Navigation Links
Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years

Trial results report no new stent thrombosis after two years in high-risk patient population

NATICK, Mass., and BARCELONA, Spain, May 22, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced four-year follow-up data from its TAXUS VI clinical trial. The data demonstrated that the safety and efficacy benefits associated with a moderate-release formulation of the TAXUS(R) Express(TM) paclitaxel-eluting stent system -- which is not approved for commercial distribution -- were maintained at four years with no new stent thrombosis reported after two years. Analysis of the data was presented by Professor Eberhard Grube, M.D., Heart Center Siegburg, Germany, the Co- Principal Investigator of the trial. The Company made the announcement at the annual Paris Course on Revascularization (EuroPCR) in Barcelona.

"Even though the moderate-release TAXUS formulation, with an 8-10 fold higher in vitro dose, was never commercialized, the excellent ongoing results in TAXUS VI further demonstrate the margin of safety of the commercial slow- release TAXUS stent now implanted in more than four million patients worldwide," said Paul LaViolette, Boston Scientific Chief Operating Officer. "With no stent thrombosis after two years, a low cardiac death rate, and a low TLR rate, we continue to be impressed with how paclitaxel performs in this high-risk patient population."

"The four-year results from TAXUS VI demonstrate that the safety and efficacy benefits associated with the moderate-release TAXUS paclitaxel- eluting stent system were maintained in patients with complex coronary artery disease at four years," said Professor Grube. "The performance of the TAXUS stent in these patients was extremely impressive when considering the complexity of their disease, including patients with long lesions, small vessels, and those requiring multiple, overlapping stents."

The randomized, double-blind, co
'"/>




Page: 1 2 3

Related medicine technology :

1. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
2. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
3. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
4. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
5. Genetic Analysis Systems Enter the Clinical Mainstream
6. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
7. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
8. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
Post Your Comments:
(Date:3/5/2015)... , March 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... second quarter ended January 31, 2015 on Thursday, March 12 ... discuss the results at 11:00 AM ET. ... 5 to 10 minutes before the beginning of the call. ... the call will be available from Thursday, March 12, 2015 ...
(Date:3/5/2015)... -- Sanomedics, Inc. (OTC: SIMH, SIMHD) ("Sanomedics" or the "Company"), ... and acquiring cutting-edge technology, products and services announced today ... at booth # 709 at the National Association ... on March 11-13, 2015 at Caesars Palace in ... The 36 th annual NAPNAP Conference will bring ...
(Date:3/5/2015)...   ndd Medical Technologies , a leader in ... ultrasound technology, announced that its EasyOne Pro® was used ... Antonio Pulmonary Fibrosis Support Group. The clinic targeted patients ... as well as those suspected of having ILD or ... 12 square inches, EasyOne Pro provides accurate respiratory test ...
Breaking Medicine Technology:Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3
... deCODE genetics,(Nasdaq: DCGN ) today announced the ... DG071, the company,s novel small-molecule modulator,of phosphodiesterase 4 ... The compound is being developed as a new ... memory loss and cognitive deficits associated,with Alzheimer,s disease ...
... Rosetta Genomics, microRNA-based,Test, miRview(TM) Squamous, Which Differentiates Squamous From non Squamous ... Methods, A Test Based on the miRview(TM) Technology First Approved for Clinical ... ... Earlier This Year, Rosetta Genomics is Expecting to Launch miRview(TM) ...
Cached Medicine Technology:deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 4Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 5
(Date:3/5/2015)... Anaheim, Calif. (PRWEB) March 05, 2015 ... plant-powered beverages, today announced at Natural Products Expo West ... drinks are now 100 percent soy and dairy free. ... 10.5-ounce single serve bottle and are packed with six ... rice protein that includes fiber, B vitamins and magnesium. ...
(Date:3/5/2015)... March 05, 2015 Califia Farms ... in the natural products coffee drinks category[1], today unveils ... Expo West in Anaheim, Calif. Concentrated Cold Brew ... Califia Café, which democratizes the next wave of the ... they need to become their own baristas. , ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 University ... university founded in 1904, has launched a new ... positive lifestyle changes. The Northwest Center for Lifestyle ... professionals, support community outreach, and conduct research in ... medicine, diet and nutrition. The center will target ...
(Date:3/5/2015)... Taking center stage at the Fort ... 9-11th is IDRevolution hosted by IDLife LLC, a ... IDLife offers a variety of nutritional products including ... to vitamin supplementation is based upon the latest ... compliant online assessment and ends with a truly ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Supply & ... annual listing of “Pros to Know” in the supply ... two members of MEBC’s leadership team were included on ... nominated and received this award due to their hard ... innovative methods for meeting and resolving client needs and ...
Breaking Medicine News(10 mins):Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 2Health News:Califia Farms Vegan Protein and New Single Serve Almondmilks to Hit Supermarket Shelves this Month 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:IDLife Partners John C. Maxwell and Troy Aikman speaking at IDRevolution in Fort Worth, TX April 9th-11th, 2015 2Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2
... , FRIDAY, Feb. 4 (HealthDay News) -- The amount of ... to grow but at a much slower rate than in ... From 2004 to 2005, spending on psychiatric drugs rose 5.6 ... and 2000, according to the Substance Abuse and Mental Health ...
... 90 percent of genital warts in men when offered before ... according to a new multi-center study led by H. Lee ... trial, which also found a nearly 66 percent effectiveness in ... to these strains, provides the first reported results of using ...
... 4 (HealthDay News) -- Experts at the American ... and treating enlarged prostate -- a common condition formally ... lead to lower urinary tract symptoms such as incontinence ... guidelines, the first since 2003, include a detailed procedure ...
... FRIDAY, Feb. 4 (HealthDay News) -- An influx of highly ... legal drugs sold as "bath salts" has law enforcement and ... director of the Louisiana Poison Center, in the first month ... nationwide from at least 25 states, compared to 234 calls ...
... failure of innovative drive in the industry, failure of the ... invest in early stage research, or failure of the Health ... funded by the Economic and Social Research Council (ESRC) shows ... be an important part of the solution to ensure a ...
... , FRIDAY, Feb. 4 (HealthDay News) -- To ... new report Friday warning that changing lifestyles linked to economic ... of several cancers. In fact, the majority of the ... million, respectively) are now occurring in economically developing countries, the ...
Cached Medicine News:Health News:U.S. Sees Slowdown in Spending on Mental Health 2Health News:HPV vaccine works for boys: Study shows first clear benefits 2Health News:Doctors Issue New Guidelines on Spotting, Treating Enlarged Prostate 2Health News:Hallucinogens Legally Sold as 'Bath Salts' a New Threat 2Health News:Hallucinogens Legally Sold as 'Bath Salts' a New Threat 3Health News:Tipping points -- the future of the pharmaceutical industry 2Health News:Cancer on the Rise in Developing Countries: Report 2
... The Advia 120 ... to streamline laboratory workflow ... benefits. This analyzer offers ... diagnostic assays, meeting the ...
The K-4500 automated hematology analyzer offers fast reliable test results of 18-parameter plus 3-histograms, valuable for effective diagnosis....
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SF-3000 automated hematology analyzer can provide accurate and precise 23-parameter hematolgy results including a fully automated WBC 5-part differential from a compact space-save design....
Medicine Products: